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Resumo 
 
 
A Esclerose Lateral Amiotrófica (ELA), uma das doenças do neurónio motor mais comum, caracteriza-
se pela perda selectiva de neurónios motores do tracto corticoespinhal. Vários estudos sugerem que a 
degeneração inicia-se na porção distal do axónio com uma progressão retrógrada. Assim, o presente 
trabalho teve como objectivo avaliar a transmissão sináptica na junção neuromuscular dos animais 
SOD1(G93A), nos períodos correspondentes às fases pré-sintomática e sintomática da ELA.  
As experiências foram efectuadas em ratinhos transgénicos SOD1(G93A) e não transgénicos (WT), na 
fase pré-sintomática (4 a 6 semanas de idade) e fase sintomática (12 a 16 semanas de idade). Após o 
nascimento, os animais foram genotipados por polymerase chain reaction (PCR). Nas respectivas fases da 
doença, os animais foram testados no rotarod, e em seguida fizeram-se registos electrofisiologicos: 
potenciais de placa evocados (EPPs), potenciais de placa miniatura (MEPPs) e  MEPPs gigantes (GMEPPs: 
MEPPs > 1mV). Os registos foram feitos em fibras musculares do diafragma inervado, paralisadas com μ-
conotoxina GIIIB. O conteúdo quântico dos EPPs foi calculado através da razão entre a amplitude média dos 
EPPs e a amplitude média dos MEPPs. 
Na fase pré-sintomática da doença, os ratos SOD1(G93A) não exibiram alterações na função motora a 
10 rpm. Relativamente à transmissão neuromuscular, estes animais apresentaram um aumento 
significativo da amplitude média dos EPPs e do conteúdo quântico dos EPPs, quando comparados com os 
animais WT, sugerindo uma maior eficiência da transmissão neuromuscular nos animais SOD1(G93A). Para 
além disso, o aumento significativo da frequência de GMEPPs, o que pela literatura parece estar associado 
a uma desregulação dos níveis intracelulares de Ca2+, e as alterações na amplitude e cinética dos MEPPs 
sugerem a existência de alterações ao nível da junção neuromuscular numa fase pré-sintomatica. Na fase 
sintomática, os animais SOD1(G93A) apresentaram um défice motor aos 10 rpm. Os registos 
electrofisiológicos revelaram a existência de dois grupos de junções neuromusculares nos ratos 
SOD1(G93A): SOD1a e SOD1b. O grupo SOD1a apresentou EPPs e MEPPs com amplitudes 
significativamente reduzidas bem como um rise-time dos MEPPs aumentado, quando comparado com os 
grupos SOD1b e WT, sugerindo um enfraquecimento da transmissão neuromuscular, nesse grupo. Pelo 
contrário, o grupo SOD1b apresentou uma transmissão neuromuscular semelhante tanto à dos animais 
SOD1(G93A) pré-sintomáticos, como também à dos WT com 12-14 semanas.  
Em conclusão, este trabalho mostra que a transmissão neuromuscular dos animais SOD1(G93A) 
encontra-se aumentada na fase pré-sintomática. Na fase sintomática, a presença de uma população mista 
de junções neuromusculares é consistente com os ciclos de desinervação/ re-inervação, já descritos 
  xii 
noutros estudos. As alterações iniciais na transmissão neuromuscular dos animais SOD1(G93A) 
representam assim mais uma evidência que os mecanismos patológicos da ELA iniciam-se antes do 
aparecimento dos primeiros sintomas. 
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Abstract 
 
 
Amyotrophic Lateral Sclerosis (ALS) is the most frequent adult-onset motor neuron disease and is 
characterized by a selective and progressive loss of motor neurons in the corticospinal tract. Growing 
evidence suggest that degeneration may begin at the distal axon proceeding in a dying-back pattern, 
increasing the need to focus on neuromuscular junction parameters. It seemed therefore of interest to 
investigate synaptic transmission at the neuromuscular junction (NMJ) in both pre- and symptomatic 
phases of the disease.  
Experiments were performed in SOD1(G93A) mice and in non-transgenic littermates (WT) with 4-6 and 
12-14 weeks-old, corresponding respectively to pre- and symptomatic phases. After birth, mice were 
genotyped through polymerase chain reaction (PCR). At the respective age, mice were submitted rotarod, 
then low-frequency (0.5 Hz) evoked endplate potentials (EPPs), miniature endplate potentials (MEPPs) and 
giant MEPPs (GMEPPs: MEPPs >1mV) were recorded from innervated diaphragm muscle fibers, paralyzed 
with μ-conotoxin GIIIB. The quantal content of EPPs was estimated as the ratio between EPPs amplitude 
and MEPPs amplitude. 
In the pre-symptomatic phase, SOD1(G93A) mice did not present motor deficits on the rotarod at 
10rpm. However, SOD1(G93A) mice exhibited a significant increase of the mean amplitude of EPPs together 
with an increase in the mean quantal content of EPPs, suggesting that more acetylcholine is being released 
into the synaptic cleft. Also, SOD1(G93A) mice presented a higher frequency of GMEPPs, suggestive of 
intracellular Ca2+ deregulation in nerve terminals. The observed increase in the mean amplitude of MEPPs 
and the decreased mean rise-time of MEPPs in SOD1(G93A) mice point as well to post-synaptic related 
changes. In symptomatic phase, SOD1(G93A) mice presented a lower motor balance and coordination. 
Electrophysiological data showed evidence for two NMJ groups in SOD1(G93A) mice: SOD1a and SOD1b. 
The SOD1a group presented both mean amplitude of EPPs and of MEPPs reduced. The mean rise-time of 
MEPPs was increased, when compared to WT and to SOD1b group, indicating an impairment in the 
neuromuscular transmission. In contrast, the neuromuscular transmission of SOD1b group was not 
different from age-matched WT or from the pre-symptomatic SOD1(G93A) mice. 
Altogether these results clearly show that the neuromuscular transmission of SOD1(G93A) mice is 
enhanced in the pre-symptomatic phase. In the symptomatic phase our results are consistent with the 
hypothesis that the diaphragm of SOD1(G93A) mice are undergoing cycles of denervation/re-innervation 
supported by the mixed population of neuromuscular junctions. These early changes in the neuromuscular 
  xiv 
transmission of SOD1(G93A) mice is a novel proof that the ALS associated events starts long before the 
symptoms appear.  
 
Keywords: Amyotrophic Lateral Sclerosis, neuromuscular transmission, SOD1(G39A) mice 
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1 Introduction 
 
1.1 Amyotrophic Lateral Sclerosis: the disease 
 
1.1.1 Disease definition and primary features 
Amyotrophic Lateral Sclerosis (ALS), also known as Charcot´s Sclerosis or Lou Gehrig´s disease, is the 
most common adult-onset motor neuron disease and the most frequent neurodegenerative disorder after 
Alzheimer and Parkinson diseases. Although its incidence is similar to that of multiple sclerosis (2-3 per 
100,000 each year), its low prevalence of just 4-6 per 100,000 each year, owing to the poor prognosis, 
understates the impact of ALS (see Boillee et al., 2006 and Dion et al., 2009).  
The primary disease hallmark is a selective and progressive degeneration of motor neurons in the 
corticospinal tracts. The consequent loss of upper motor neurons, which are found in the motor cortex, 
triggers spasticity and hyper-reflexia while that of lower motor neurons, present in the brainstem and 
spinal cord, leads to widespread muscle weakness, atrophy and paralysis. This disorder is diagnosed in 
midlife (usually between age 45 and 60) and patients die once denervation reaches the respiratory muscles 
and diaphragm, that is 1 to 5 years after symptoms onset (see Gonzalez de Aguilar et al., 2007).   
Most cases (90%) do not present a hereditary pattern and are hence classified as sporadic ALS. 
Increasing evidence suggest the involvement of genetic factors, with susceptibility genes increasing the 
overall risk for neurodegeneration, as well of epigenetics.  The remaining 10% are termed familial ALS and 
the disease is frequently inherited in an autosomal dominant manner.  Over the past two decades, 13 
genes and loci have been reported to predispose to ALS. However, both forms produce similar pathological 
and clinical hallmarks suggesting a common pathogenesis (see Boillee et al., 2006; Kiernan et al., 2011). 
Despite many advances in investigative medicine over the past decades, there is no diagnostic test for 
ALS. Clinicians have to identify a combination of diagnostic features and classify patients into categories 
according to the level of diagnostic certainly, which is a method of detection with very poor sensitivity 
particularly in the early stages of the disease. Regarding the management of ALS, there is no prophylactic or 
curative treatment for ALS. The 2-amino-6-trifluoromethoxy-benzothiazole (Riluzole) (Mizoule et al., 1985) 
is the only approved disease-modifying agent that has been shown to prolong survival of ALS patients by a 
few months (Bensimon et al., 1994; Miller et al., 2003). Riluzole exerts its neuroprotective effects by 
blocking both voltage-gated sodium channels (Na+) and N-methyl-D-aspartate (NMDA) receptors thereby 
preventing excessive calcium influx into neurons (Hubert et al., 1994; Malgouris et al., 1994). 
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1.1.2 Cellular and molecular mechanism underlying ALS 
Cu/Zn superoxide dismutase mutation 
First insights into the cellular and molecular basis of ALS began with the identification of mutations in 
the copper/zinc superoxide dismutase gene (Cu/Zn, SOD1) (Rosen et al., 1993), accountable for 
approximately 20% of familial cases and 5% of apparently sporadic ALS (see Kiernan et al., 2011). Wild-type 
SOD1 is an abundant homodimeric and cytosolic enzyme ubiquitously expressed. This polypeptide 
comprises 153 amino-acid and is responsible for the conversion of superoxide radicals, a by-product of 
mitochondrial respiration, into molecular oxygen and hydrogen peroxide, as follows; 
2O2
- + 2H+                 H2O2 + O2 
Copper atom, which binds one of the monomers, plays the active role in the removal of superoxide 
whereas zinc atom, bound to the other monomer, confers structural stability to the enzyme. This two-step 
process prevents the generation of reactive oxygen species (ROS), and hence, reduces oxidative stress in 
cells (see Cozzolino et al., 2008; Dion et al., 2009). 
Currently, more than 130 different SOD1 mutations have been reported to cause ALS. These mutations 
are distributed throughout all five exons of the gene and most of them are point mutations affecting either 
the active site or the structure (see Cozzolino et al., 2008; Dion et al., 2009). Since SOD1-knockout mice do 
not present neurodegeneration (Reaume et al., 1996) and many SOD1 variants show normal (Gurney et al., 
1994; Wong et al., 1995) or no enzymatic activity (Ripps et al., 1995; Bruijn et al., 1997), those mutations 
are responsible for imparting an additional toxic function rather than inducing a reduction or loss of 
superoxide scavenging activity (see Dion et al., 2009). 
 
Model for the evolution 
ALS is considered a multifactorial disease, as it results from a complex interplay between multiple 
pathological mechanisms. Also, it is considered a multisystemic disease (Pramatarova et al., 2001; Gong et 
al., 2000), where damage within motor neurons is determinant for disease initiation whereas damage 
within non-neuronal cells drives disease progression and spread (Clement et al., 2003; Boillee et al., 2006). 
Most of the current knowledge about cellular and molecular events taking place during disease 
progression (figure 1.1) has come from studies with multiple animal models. During the early phase of the 
disease, where there are no clinical signs, mutant SOD1 primarily acts within motor neurons causing the 
early retraction of motor axons from their synapses at the neuromuscular junction (Frey et al., 2000; 
Fischer et al., 2004; Pun et al., 2006). The mutant protein is also known to disrupt several cellular 
SOD1 
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machineries such as mitochondria (Dal Canto and Gurney 1994; Wong et al., 1995; Kong and Xu 1998), 
axonal transport (Wong et al., 1995; Zhang et al., 1997; Williamson and Cleveland 1999), endoplasmatic 
reticulum (Atkin et al., 2006) and proteasome (Urushitani et al., 2002; Kabashi et al., 2004).  
During the symptomatic phase, there is a massive activation of microglia (Hall et al., 1998) and 
astrocytes (Schiffer et al., 1996; Hall et al., 1998) besides the continuing damage within motor neurons. 
Mutant SOD1 acts within these non-neuronal neighbors triggering a reduction in the levels of the glutamate 
transporter (EAAT2) (Bruijn et al., 1997, Howland et al., 2002), thereby promoting excitotoxicity in motor 
neurons, as well as a reduced secretion of trophic factors and/or release of toxic factors (Elliott 2001; 
Hensley et al., 2003). The build-up of damage within motor neurons, due to both intrinsic and extrinsic 
factors, ultimately triggers the activation of a caspase-depedent cell suicide program (Raoul et al., 2002; 
Wengenack et al., 2004). Consequently, denervation leads to the widespread muscle weakness and later to 
the progressive paralysis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Model for the progression of ALS (from Boillee et al., 2006) 
The early phase of the disease starts with the retraction of motor axons from their synapses. Aggregates 
containing missfolded SOD1 damage mitochondria, reducing ATP production and increasing free Ca2+ 
release, the endoplasmatic reticulum and the proteasome. Also, the disorganization of neurofilaments 
and/or mitochondrial defects lead to disruption of axonal transport. During symptomatic phase, mutant 
SOD1 triggers the inactivation of the glutamate transporter (EAAT2) in astrocytes, leading to an excessive 
influx of Ca2+ into lower motor neurons. In addition, activated microglia and astrocytes by reduced 
secretion of trophic factors or/and release of toxic factors into the cellular environment, amplify the initial 
damage and drive the progression of the disease. The end stage is characterized by paralysis and muscle 
atrophy with caspase-depedent cell death. 
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1.1.3 The dying-back and dying-forward hypothesis 
At present, there is controversy whether disease starts distally, centrally or independently in upper 
motor neurons and lower motor neurons. The dying-forward hypothesis proposes that disease begins 
primarily in motor cortex, with upper motor neurons mediating in a latter phase the anterograde 
degeneration of lower motor neurons (by glutamate-induced excitotoxicity). The dying-back hypothesis, on 
the other hand, stands up for an initiation at the motor endplate, with a retrograde degeneration (see 
Kiernan et al., 2011). 
 
Evidence for dying-back hypothesis 
In the past decades, several studies that explored the spatio-temporal changes in motor neuron 
pathology in ALS (summarized in table 1.I) have been pointing to a retrograde degeneration. Both Frey and 
collaborators (2000) and Fisher and collaborators (2004) were the first groups to detect an early 
detachment of motor axons from their synapses at the neuromuscular junction in pre-symptomatic 
SOD1(G93A) mice, stating a dying-back axonopathy. Indeed, endplates denervation and motor axons loss 
were detected before soma degeneration and symptoms onset (Fischer et al., 2004), and fast-fatigable 
neuromuscular junctions presented a higher vulnerability to degeneration than slow-type synapses, 
thereby being lost early on (Frey et al., 2000). 
The assessment of functional motor units loss in SOD1(G93A) mice by Hegedus and colleagues (2007; 
2008) reinforced the dying-back hypothesis. These authors found a decline in motor unit numbers in fast-
twitch muscles from day 40 and a concomitant decline in whole muscle contractile force. Later, they 
reported a preferential vulnerability of large motor units innervating IIB and IID/X fast-fatigable muscle 
fibers, together with a conversion to motor units innervating IIA fast-resistant muscle fibers.  
More recently, a longitudinal MRI study performed by Marcuzzo and colleagues (2011) in the 
SOD1(G93A) mice revealed that muscle degeneration precedes neurodegeneration and clinical signs, 
supporting the retrograde dying-back of motor neurons. 
 
Muscle as the primary site of degeneration 
Besides the dying-back hypothesis, some studies suggest that skeletal muscle is the primary site of 
toxicity and the cause of the retraction of motor axons. Dupuis and colleagues (2002) demonstrated a shift 
in muscle gene expression, with an up-regulation of the neurite outgrowth inhibitor Nogo–A, in skeletal 
muscle from SOD1(G93A) mice and ALS patients. This suggests that muscle can play a key role in initiating 
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and modulating the disease, a finding consistent with the positive outcomes of treatments acting on muscle 
fibers, as IGF1 (Dobrowolny et al., 2005).  
Moreover, it was detected that SOD1(G93A) mice suffer from a dramatic defect in energy homeostasis 
that seems to be linked to an abnormal hypermetabolism mainly of muscular origin (Dupuis et al., 2004). 
Consistent with this hypothesis, a mouse model of muscle restricted mitochondrial defect (similar to the 
hypermetabolism) is able per se to destabilize neuromuscular junctions and generate motor neuron 
degeneration (Dupuis et al., 2009).  
Finally, Wong and colleagues (2010) showed that the restricted expression of the mutant SOD1 in 
muscle is sufficient to trigger motor neuron degeneration with a phenotype consistent with ALS.  
 
1.2 The neuromuscular junction 
The neuromuscular junction is the synapse between a spinal motor neuron and a skeletal muscle fiber. 
This system is responsible for transmitting the electric impulse from the nervous system to the muscle, 
triggering muscle contraction.  
 
1.2.1 Structure of the neuromuscular junction 
In mostly higher vertebrates, each skeletal muscle fiber is innervated at a single site by a single motor 
axon. As the motor neuron approaches the muscle fiber, the axon loses its myelin sheath and divides into 
fine branches. The ends of the branches form multiple expansions, called synaptic boutons, which make 
synaptic contacts with the muscle fibers membrane at a specialized region, the motor the endplate (Kandel, 
2000). 
Each nerve ending contains all the machinery required to release the neurotransmitter including 
synaptic vesicles, voltage-gated calcium channels (Ca2+) and numerous mitochondria. Synaptic vesicles (also 
termed quanta) store acetylcholine (ACh) which is the only neurotransmitter at the skeletal neuromuscular 
junctions. ACh is first produced locally from acetyl coenzyme A (acetylCoA, synthesized from glucose) and 
choline (transported from the plasma) by choline acetyltransferase (ChAT) and then loaded into vesicles 
through vesicular transport (Purves, 2001).   The number of ACh molecules inside a single vesicle, termed 
quantum of transmitter, varies from 500 to 10 000 (Kuffler and Yoshikami 1975) and was shown to vary 
with the functional state of the nerve terminal (Brooks and Thies, 1962; Naves and Van der Kloot, 2001). 
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Table 1.I. Major studies performed in SOD1 model of ALS and pointing for a dying-back pathology. 
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Synaptic vesicles can be attributed to three functionally different pools. The readily releasable pool 
comprises synaptic vesicles clustered at active zones, the specialized region for transmitter vesicular 
release, and sustains low and moderate neurotransmission. The cycling pool, located near the active zones, 
ensures the replenishment of the readily releasable pool. Recycled synaptic vesicles can either incorporate 
the readily releasable or the cycling pool. Finally, the reserve pool, located further away, sustains the 
replenishment of the below pools and is recruited only upon long-term transmission (Richards et al., 2003, 
see Rizzoli and Betz 2005). 
The space between the nerve and muscle fibers is termed the synaptic cleft and consists in a 
condensed extracellular matrix (basement membrane or basal lamina) composed of collagen and 
glycoproteins with a structural function in organizing the synapse. Both the nerve and muscle fibers secrete 
proteins into the basement membrane namely acetylcholinesterase (AChE). This is a high catalytic enzyme 
that, by cleaving ACh into acetate and choline, limits both temporal and spatial extent of transmitter action 
(Kandel et al., 2000). 
The motor endplate is characterized by a deep folding of the sarcolema. The crests contain a high 
density of ACh receptors, whereas the depths present a high density of voltage-gated sodium channels 
(Na+). Post-synaptic actions of ACh are mediated by the ionotropic nicotinic ACh receptors, which are non 
selective cation channels (Kandel et al., 2000). 
 
1.2.2 Neuromuscular transmission 
Most of the knowledge on synaptic transmission comes from the pioneering work on neuromuscular 
transmission performed by Bernard Katz and his colleagues during the 1950s and 1960s. 
 
Resting membrane potential 
The resting membrane potential (RMP) is the electrical potential measured across the cell membrane 
in the absence of signaling. It results from a separation of charges that, in general terms, is due to 
differences 1) in the concentrations of specific ions across cell membrane and 2) in the selective 
permeability of the membrane to some of these ions. The negative membrane potential indicates an excess 
in negative charges within the cell, and can be predicted by the Goldman equation; 
  PK[K
+]o + PNa[Na
+]o + PCl[Cl
-]i 
PK[K
+]i + PNa[Na
+]i + PCl[Cl
-]o 
 
RMP =                   ln    
RT  
 F   
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Where R indicates the gas constant, T the temperature, F the faraday constant, P the permeability of the 
membrane for the ion X, and [X]o and [X]i the concentrations of the ion inside and outside the muscle fiber. 
In these conditions, cells are in a steady state with no net flux of ions across the membrane.  
During synaptic transmission, the temporary opening of ion channels produces brief changes in the 
flow of electrical current across the cell membrane that drives the membrane potential away from its 
resting value (Purves, 2001; Kandel et al., 2000). 
 
Evoked activity 
During nerve stimulation, the action potential propagating along the axon reaches the nerve terminal 
and the resulting depolarization causes the opening of voltage-gated Ca2+ channels. The subsequent influx 
of Ca2+ raises the intracellular free Ca2+ concentration in the pre-synaptic terminal triggering the 
synchronous fusion of the synaptic vesicles with the pre-synaptic membrane. The number of quanta 
released by each nerve impulse is known as quantal content of the EPP. 
In the post-synaptic membrane, the activation of nicotinic ACh receptors by two molecules of ACh 
increases the total conductance of the endplate membrane, allowing Na+ and K+ to flow with nearly equal 
permeability. This local depolarization, called the endplate potential (EPP), is normally large enough to 
bring the membrane potential of the muscle fiber above the threshold for the activation of voltage-gated 
Na+ channel. By a positive feedback loop, more voltage-gated Na+ channels are activated, producing an 
actively propagated action potential that ultimately triggers muscle contraction (Purves, 2001; Kandel et al., 
2000). 
 
Spontaneous activity 
In the absence of nerve stimulation, spontaneous deflections of the resting membrane potential are 
also detected (Fatt and Katz 1952). These small depolarizations (<1 mV) are designated miniature endplate 
potentials (MEPPs) and arise from the spontaneous asynchronous release of individual vesicles. “Giant” 
miniature endplate potentials (GMEPPs) (Liley 1957) are classified separately from the usual MEPPs. These 
arise from a spontaneous synchronous release of multiple vesicles insensitive to both nerve terminal 
depolarization and extracellular Ca2+ (Colmeus et al., 1982; Thesleff et al., 1983) being instead triggered by 
Ca2+ released from intracellular stores and/or result from an impaired processing of recycled vesicles (Rizzoli 
and Betz 2002). Moreover several studies reported an increased frequency of GMEPPs in re-innervated 
muscles (Miledi 1960), nerve terminals in degeneration (Birks et al., 1960) and in motor endplate diseases 
(Weinstein 1980).   
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Safety factor 
The transmission of signals from nerve to skeletal muscle is a highly reliable process that is necessary 
for the normal function of the body. Motor nerve terminals release more quanta per nerve impulse than 
the required to initiate an action potential. This excess is referred as safety factor and allows the 
neuromuscular transmission to remain effective under several physiological conditions and stresses. 
Numerous diseases characterized by an impairment of neuromuscular transmission, and therefore by a 
weakness of voluntary contraction, present a reduced safety factor (see Wood and Slater 2001). 
 
1.3  ALS and the neuromuscular junction 
 
1.3.1 Molecular changes 
Mitochondria and axonal transport are considered key players in many cellular processes relevant for 
neuromuscular transmission and their impairment, as reported in ALS, might be related to changes in 
neuromuscular junction function. 
Mitochondria are vital organelles with a predominant role in energy metabolism providing ATP for 
axonal transport, ion pump fueling (Na+/K+), neurotransmitter synthesis, and for several steps in the vesicle 
cycle such as vesicle fusion, uncoating and refilling. This metabolite is also essential to sustain 
neurotransmission during high-frequency stimulation mediating the mobilization of vesicles from the 
reserve pool and recycling via endocytosis. Mitochondria are specifically retained in regions of the axon 
with high energy-demand including Ranvier nodes and nerve terminals in particular near the actives zones 
(Vos et al., 2010 and Kawamata and Manfredi 2010). In ALS, mutant SOD1 was reported to accumulate in 
vacuoles in the mitochondrial intermembrane space (Higgins et al., 2003). In accordance, defects in the 
mitochondrial respiratory chain (ATP-generating oxidative phosphorylation) were observed in both ALS 
patients tissues (Wiedemann et al., 2002) and transgenic mice (Mattiazzi et al., 2002). Moreover, mutant 
SOD1 was also reported to disrupt anterograde transport of mitochondria, inducing an accumulation of 
mitochondria in cell bodies and in proximal axons of transgenic mice (De Vos et al., 2007). Consistent with 
this, the reduced mitochondrial content in the distal axon combined with the impaired mitochondrial 
function may lead to a local ATP depletion, thereby inducing axonal stress and compromising 
neuromuscular transmission (De Vos et al., 2007).  
Mitochondria also contribute to neuronal function through regulation of calcium homeostasis. This 
organelle is able to sequester and release Ca2+ and thereby modulates numerous events such as the 
probability of neurotransmitter release (promoting either recovery from depression or vesicles depletion), 
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and the endocytic rate within vesicle recycling process (see Vos et al., 2010; Kawamata and Manfredi 2010). 
In ALS, motor nerve terminals present a lower cytosolic calcium clearance (Vila et al., 2003; Jaiswal et al., 
2009; Nguyen et al., 2009) and muscle fibers present both reduced mitochondrial Ca2+ uptake and 
increased Ca2+ release from endoplasmatic reticulum stores (Zhou et al., 2010). This reduction in calcium 
buffering leads to an increase in intracellular calcium levels making motor neurons more vulnerable to 
degeneration (Siklos et al., 1998; Kim et al., 2002). 
Finally, mitochondria constitute an important source of reactive oxygen species (ROS) through 
mitochondrial respiration (Vos et al., 2010 and Kawamata and Manfredi 2010). Hydrogen peroxide (H2O2), 
which is generated from the superoxide by SOD1, was reported to be a modulator of transmitter release. 
While low physiological concentrations of H2O2 were shown to facilitate neuromuscular transmission by 
enhancing transmitter release (Giniatullin and Giniatullin 2003), high concentrations caused synaptic 
depression through a direct impairment of the releasing machinery, mediated by SNAP25 essential fusion 
protein (Giniatullin and Giniatullin 2003, Giniatullin et al., 2006). In ALS, multiple pathological studies have 
reported evidence of increased oxidative stress in postmortem tissue from patients (Shaw et al., 1995; 
Simpson et al., 2004). 
Motor neurons are polarized and contain long processes, often with more than a meter in length, 
through which cargoes have to move.  Axonal transport is therefore a key component in structure 
maintenance and signal transmission, namely neurotransmitter synthesis, release and recycling, at the 
nerve terminals of motor axons. In ALS, mutant SOD1 species were shown to bind KAP3, a component of 
the kinesin-2 motor complex that mediates the transport of ChAT. Consistent with this, both ChAT levels at 
nerve terminals and ACh release, were reduced (Tateno et al., 2009). 
 
1.3.2 Functional changes 
Figure 1.2 illustrates the current knowledge on neuromuscular transmission in ALS. At present, there is 
little information regarding pre-symptomatic phase.  Souayah and colleagues (2012) reported that 6 weeks-
old SOD1(G93A) mice presented a reduced probability of successful neuromuscular transmission (more 
failures) at high frequencies of stimulation (70 and 90 Hz). This functionally compromised phenotype was 
attributed by the authors to an impaired action potential initiation and propagation along the axon or 
impairments in transmitter mobilization and release from the nerve ending.  
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Figure 1.2 Current knowledge on neuromuscular transmission in ALS  
Here is summarized the results from major electrophysiological studies in both pre-symptomatic and 
symptomatic phases of ALS disease. Grey boxes show studies performed in mice models of ALS whereas 
white boxes show studies performed with samples from ALS patients. In pre-symptomatic phase, Souayah 
and colleagues (2012) assessed neuromuscular transmission of 6weeks-old SOD1(G93A). In symptomatic 
phase, Kim (1996) and Naumenko (2011) groups looked at neuromuscular transmission of SOD1(G93A) and 
congenic SOD1(G93A) mice respectively, when both models started to show signs of disease. 
Electrophysiological recordings in anconeus muscle biopsies from ALS patients (Maselli et al., 1993) or in 
WT mice passively transferred with sera from sporadic ALS patients (O'Shaughnessy et al., 1998) were also 
studied. ↗indicates an increase↘,a decrease and =no changes when compared to the control. QC, quantal 
content; EPP, endplate potential; MEPPs, miniature endplate potentials; RRP, readily releasable pool. 
 
Regarding symptomatic phase, contradictory results were published. Maselli and colleagues (1993) 
reported that anconeus muscle biopsies taken from ALS patients presented an impaired neuromuscular 
transmission with a reduced mean quantal content of EPPs, mean quanta available for immediate release, 
as well as mean quantal stores. Whereas the mean frequency of MEPPs remained unchanged, the mean 
amplitude of MEPPs was similarly decreased. Naumenko and colleagues (2011) however did not observed 
Cg.SOD1(G93A) mice (early sympt) 
(Naumenko et al., 2011) 
Amplitude and QC of EPPs (=) 
RRP in males (↘) 
Frequency of MEPPs (↘) 
 
 
SOD1(G93A) mice (pre-symp) 
(Souayah et al., 2011) 
Failures of EPP (70; 90 Hz) (↗) 
Amplitude of MEPPs (=) 
 
 
SOD1(G93A) mice (early sympt) 
(Kim et al., 1996) 
QC (↗) 
Frequency MEPPs (=) 
Frequency GMEPPs (altered) 
 
Biopsies from ALS patients 
(Maselli et al., 1993) 
QC of EPPs (↘) 
RRP and Quantalstores (↘) 
Frequency of MEPPs (=) 
Amplitude of MEPPs (↘) 
 
 
 
WT mice + ALS sera 
(O´Shaughnessy et al., 1998) 
Amplitude and QC of EPPs (↗) 
EPP failure rate (↘) 
Frequency of MEPPs (↗) 
Amplitude of MEPPs (=) 
 
Pre-symptomatic phase                                          Symptomatic phase 
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differences in the amplitude and quantal content of EPPs in symptomatic congenic SOD1(G93A) transgenic 
mice. Whereas there was a dramatic drop in spontaneous activity with a reduced mean frequency of 
MEPPs, no alterations in the amplitude of MEPPs were detected. Male neuromuscular junctions were also 
reported to present a reduced readily releasable pool and to be more vulnerable to reactive oxygen 
species. In contrast, a preliminary study performed by Kim and colleagues (1996) detected an increased 
mean quantal content in symptomatic SOD1(G93A) mice (10-12 weeks-old) and no changes in both 
frequency and amplitude of MEPPs. Although no details were provided by the authors, the frequency of 
GMEPPs was reported to be changed.  
Interestingly, the passive transfer of sera from sporadic ALS patients to wild-type mice increased the 
evoked transmitter release (amplitude and mean quantal content) and spontaneous activity (frequency of 
MEPPs) (O'Shaughnessy et al., 1998). In accordance, either passive transfer or pre-incubation of 
neuromuscular junctions with immunoglobulins G (IgGs) from ALS patients had already been reported to 
increase the frequency of MEPPs (Uchitel et al., 1988; Uchitel et al., 1992). Consistent with this, Pagani and 
colleagues (2006) showed that IgGs from ALS patients interacted with nerve terminals potentiating 
spontaneous release through the activation of both N-type (CaV2.2) channels and IP3 receptors, and 
Gonzalez and colleagues (2011), through P/Q-type (CaV2.1) channels. 
 
  13 
2 Goals 
 
 
ALS is the most frequent adult-onset motor neuron disease. Currently, numerous authors have been 
pointing for a dying-back disease. Since the neuromuscular junction might be the first site to be affected 
and, therefore, where first signs of the disease can be detected at early stages, there is a need to focus on 
neuromuscular junction parameters.  
At present there is little information about neuromuscular transmission in the SOD1(G93A) mice, and 
the existing one is often controversial. We considered therefore of interest to evaluate neuromuscular 
function with the following specific goals: 
1. To investigate if the evoked and spontaneous neuromuscular transmission is impaired in pre-
symptomatic phase of the disease, 
2. To investigate if the evoked and spontaneous neuromuscular transmission is impaired in 
symptomatic phase of the disease, 
3. To investigate if symptomatic transgenic mice present differences in evoked and 
spontaneous neuromuscular transmission when compared to pre-symptomatic transgenic 
mice. 
 
To meet the previous aims we performed the following tasks: 
1. Establishment and maintenance of the SOD1(G93A) colony at IMM facilities, 
2. Litters genotyping in order to distinguish transgenic from non-transgenic mice, 
3. Behavioral phenotyping to evaluate motor function and validate therefore the phase of the 
disease. 
4. Intracellular recordings in phrenic-nerve diaphragm preparations from transgenic and non-
transgenic mice in two age groups: 4-6 and 12-14 weeks-old corresponding respectively to 
pre-symptomatic and symptomatic phases of ALS. 
  
  14 
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3 Materials and methods 
 
3.1 Animals 
 
3.1.1 Animal model 
Animal models are of extreme importance since they constitute a major tool to explore the etiology 
and pathogenesis of diseases and to test possible therapeutic approaches. In the framework of ALS, as most 
human samples are obtained from patients at the terminal stage, the investigation of pathogenic 
mechanisms operating from disease onset to death becomes nearly impossible without resorting animal 
models (see Kato 2008). 
 
Table 3.I. Characteristics of main mutant SOD1 mouse models (adapted from Swarup and Julien 2011) 
SOD1 mutant 
(Reference) 
Inheritance 
Enzyme 
Activity 
Protein 
stability 
Disease 
onset 
Disease 
Progression 
G93A 
(Gurney et al. (1994) Science) 
Dominant 
Active 
(11 fold) 
Stable 
Early 
(3-4 mo) 
Moderate 
(3 wks) 
G86R 
(Bruijn et al. (1997) Neuron) 
Dominant 
Inactive 
(0 fold) 
Reduced 
Late 
(7,5mo) 
Fast 
(2wks) 
G37R 
(Wong et al. (1995) Neuron) 
Dominant 
Active 
(14.5 fold) 
Reduced 
Moderate 
(4-6 mo) 
Slow 
(4-6 wks) 
 
The generation of ALS animal models started after the identification of sod1 as a causative gene for 
this disease (Rosen et al., 1993). Until now more than 12 transgenic mice carrying different SOD1 mutations 
have been created by inducing the expression of mutant sod1 mini-genes. These are constructs involving 
typically 12-15kb human genomic fragments, encoding mutated SOD1, driven by endogenous promoter 
and regulatory sequences (see Turner and Talbot 2008). Table 3.I presents the characteristics of major 
SOD1 transgenic lines. As illustrated, these lines differ in transgene copy number, enzyme levels and 
activity, as well as disease onset and progression. Despite the vast differences, all of them have been 
reported to exhibit the same histopathological hallmarks that are observed clinically in both sporadic and 
familial ALS  (see Julien and Kriz 2006). More importantly, mice that express wild-type human SOD1 do not 
develop this stereotyped syndrome suggestive of motor neuron disease (Gurney et al., 1994). More 
recently, the discovery of other genes implicated in ALS namely alsin, dynactin, senataxin, VAPB, FUS and 
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TDP-43, has lead to the creation of new animal models. Nevertheless, SOD1 models remain the only 
reliable mouse model for either sporadic or familial ALS (see Swarup and Julien 2011). 
In the present study we used the SOD1(G93A) model (Gurney et al., 1994) since it constitutes the most 
widely used and the best-characterized mouse model of ALS, as illustrated in figure 3.1. These animals carry 
a high copy number (25±1.5) of the human SOD1 gene (transgene) with a point mutation responsible for a 
glycine to alanine substitution at position 93. 
 
 
 
Figure 3.1 Time course of clinical and neuropathological events in SOD1(G93A) mice (from Turner and 
Talbot 2008) 
Clinically, mice begin to show signs of hind limb tremor and weakness by 3 months of age. From 3 to 4 
months, mice progress to hyper-reflexia, paralysis and premature death. At the cellular level, 
neurodegeneration begins with denervation of neuromuscular junctions, followed by a significant axonal 
loss and soma loss. A massive activation of astrocytes and microglia becomes visible at approximately 
disease onset. Finally, at the molecular level, pathologic features of motor neurons include mitochondrial 
vacuolization, Golgi apparatus fragmentation, neurofilament-positive inclusions, mutant SOD1 aggregation 
into insoluble protein complexes (IPC) (Turner and Talbot 2008). 
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3.1.2 Animal strains, breeding and husbandry 
Transgenic B6SJL-TgN(SOD1-G93A)1Gur/J males (Jackson Laboratory, No. 002726) and wild-type 
B6SJLF1/J females were purchased from Jackson Laboratory (USA) and a colony was established at BEEM 
facilities. Since transgenic females are infertile, mice were maintained on a background B6SJL by breeding 
transgenic males with non-transgenic females in a rotational scheme.  
At time of weaning, littermates were identified through ear punching and separated in different cages 
according to their gender. This system is a permanent procedure that attributes to each hole a number and 
so allows individual identification of mice. Moreover, this method does not require anesthesia, guarantee 
animal welfare, and the tissue removed by the ear punch can be used for DNA analysis, phasing out the 
requirement of an additional procedure. All animals were housed 4-5 mice/cage, under a 12h light/12h 
dark cycle, and received food and water ad libitum. Animals were handled according to European 
Community guidelines and Portuguese Law on Animal Care. 
 
3.2 Genotyping 
A polymerase chain reaction (PCR) was then conducted to differentiate between non-transgenic and 
transgenic mice. Ear tissue punches taken from each mice were placed separately in microcentrifuge tubes 
along with 0.1ml of DNA digestion buffer (50mM KCl, 10nM Tris-HCl (pH 9.0) and 0.1% Triton X-100 with 
proteinase K added to a final concentration of 0.15 mg/ml) and were incubated overnight at 56ºC. A gentle 
shaking was applied in order to aid complete tissue disruption. After incubation, proteinase K was 
inactivated by placing tubes in a dry heating block set at 95ºC for 15min. Samples were then centrifuged for 
2 min at 1200rpm to get rid of debris and supernatants were transferred into new autoclaved eppendorfs 
tubes. DNA samples were either used immediately as templates for amplification reaction or stored at -
20ºC. 
 
Table 3.II. Protocol Primers (adapted from Jackson´s Laboratories manual) 
Primer Sequence 5' --> 3' Primer Type 
oIMR0113 CAT CAG CCC TAA TCC ATC TGA SOD1 Transgene 
oIMR0114 CGC GAC TAA CAA TCA AAG TGA SOD1 Transgene 
oIMR7338 CTA GGC CAC AGA ATT GAA AGA TCT Internal Positive Control Forward 
oIMR7339 GTA GGT GGA AAT TCT AGC ATC ATC C Internal Positive Control Forward 
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A mix solution was prepared (15.7µl H2O autoclaved, 2.50µl 10xPCR Buffer II, 2.5mM of each dNTPs, 
20µM of each primer (presented on table 3.II) and 5U/µl Taq DNA polymerase, to a final volume of 
25µl/sample), taking into account the number of DNA samples and controls to run, plus 10% extra for 
losses while pipeting. IMR0113 and IMR0114 amplify SOD1 human fragment while IMR7338 and IMR339 
amplify a internal positive fragment. After pipeting 25µl of the mix reaction into PCR tubes, 1µl of each DNA 
sample was added, and tubes were placed in a termocycler device for PCR assay. After an initial 
denaturation step of 3min at 94ºC, DNA was amplified for 29 cycles (30s at 94ºC, 30s at 62ºC and 30s at 
72ºC) followed by a final elongation step of 10 min a 72ºC and a cool down step, where solutions are 
maintained at 4ºC. 
Finally, PCR products were separated on a 2% agarose gel. To do that, 5µl of loading buffer was added 
to each sample tube, and then 15µl of the mixture was loaded to the gel-well.  To allow band size 
estimation, 6µl of the BenchTop 100bp DNA ladder was also applied. Gel was run for 30 to 40min at 100 
volts in an electrophoresis bath containing 1x Tris-Acetate-EDTA (TAE) buffer and then placed under UV 
light for band inspection. Figure 3.2 shows an example of a progeny genotyping with the SOD1 and WT 
bands on the agarose gel. Wild-type mice present a unique band of 324pb corresponding to the internal 
positive control, while transgenic mice exhibits 2 bands, the 236pb and 324bp corresponding to the 
transgene and internal positive standard respectively. 
 
 
 
 
 
 
 
 
Figure 3.2 Example of a progeny genotyping 
Here is illustrated the identification of SOD1 and WT mice on a 2% agarose gel. On the left side is the 
BenchTop 100bp DNA ladder separated equally on a 2% agarose gel. The PCR product of the WT genotype 
(lane 11) is a fragment of 324bp whereas the one of SOD1 mice (lane 5) are two fragments of 236 and 
324bp. Lane under M in the gel is the 100bp size marker. 
M     1     2      3    4      5     6      7      8      9   10    11    12 
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3.3 Behavioural phenotyping 
 
3.3.1 Body weight 
Body weight is easy to measure and can be indicative of general wealth of mice. However, the 
correlation between the process of weight loss and changes in locomotor coordination and muscular 
strength is difficult (Knippenberg et al., 2010). In this way body weight was recorded has an additional 
parameter. 
 
3.3.2 Rotarod test 
At present, rotarod is considered the gold standard test to assess motor function in mice (see Brooks 
and Dunnett 2009). As shown by Knippenberg and colleagues (2010), is the most sensitive and appropriate 
method for early detection of symptoms onset in the SOD1(G93A) mouse model. The rotarod apparatus is 
illustrated in figure 3.3. Briefly, mice are placed on the rotating rod where they have to maintain their 
balance and motor coordination to remain on it. When mice fall from the rod, sensing platforms (a trip 
switch on the floor below) stop the counter and latency-to-fall is recorded. This test can be performed at 
fixed or accelerating speeds.  Fixed-speed test are known to provide separate data on each range and does 
not confound motor coordination with fatigue as the accelerating test do. In addition, this version was 
reported to be more appropriate to detect small changes with a maximum sensitivity (Monville et al., 2006; 
Brooks and Dunnett 2009)  
 
 
Figure 3.3 Rotarod device  
Mice falling from the rotating rod push the platforms. This stops the counter and in this way the latency-to-
fall is recorded.  
Rotating rod 
Sensing platforms 
Counter 
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In the context of ALS, multiple rotarod protocols have been generated. Most of them were used to 
assess disease onset and progression while testing new drug treatments and so where performed in an 
overtime fashion. Typically, fixed speed tests are performed at 10 or 15 rpm with a cut-off time set at 180s 
(Smittkamp et al., 2008; Banerjee et al., 2008) and accelerating versions increase speed from 2 to 20 rpm 
over the course of 300s (Smittkamp et al., 2008) or 1 to 18 rpm during 180s (Knippenberg et al., 2010). 
In the present study rotarod was conducted in two age groups: in animals with 4-6 and 12-14 weeks.  A 
training period comprising two stages was performed so as to minimize environmental variability. First 
animals were habituated to handling, initiated four days before the testing day, then to the rotarod 
apparatus and finally were taught the task itself. For that, mice were placed on the rod at the lowest 
rotation speed (4 rpm) where they had to maintain for at least 120s. Once the task was learnt, mice were 
placed and taken off from the rod several times by the researcher in order to reduce handling stress (Rozas 
et al., 1997). In the testing day, mice were sequentially assessed at 5, 10, 15, and 25 rpm, for a maximum of 
300s each speed. 3 trials were performed per speed with 5 min rest between each trial. 
 
3.4 Electrophysiological recordings 
 
3.4.1 The neuromuscular junction model 
Since the turn of the century, the neuromuscular junction of vertebrate skeletal muscle has served as a 
model for studying synaptic transmission conveying most of our current knowledge about 
neurotransmission within central and peripheral nervous system.  
This synapse has been considered a prototype model due to its accessibility (located at periphery), 
size, and more importantly its simplicity, facilitating the experimental analysis (Deschenes et al., 1994).  
Indeed, each muscle fiber is innervated by a single motor neuron, so any event occurring in this cell results 
from just one input. This is not the case in central nervous system where one neuron can receive a 
thousand of different inputs, either excitatory or inhibitory, from adjacent neurons. Additionally, the only 
input is excitatory and results from the action of ACh. This neurotransmitter is released in multimolecular 
packets or quanta, and the number of quanta release by an EPP, that is the quantal content, can be easily 
assessed. Finally, since the amplitude of any synaptic potential depends upon both the amount of 
transmitter released and the postsynaptic responsiveness to transmitter, the differentiation between pre 
and post-synaptic factors becomes possible. Typically changes in MEPPs frequency are related to the pre-
synaptic component. Changes of MEPPs amplitude may reflect both pre- and postsynaptic factors. 
Generally it results from changes in post-synaptic action of ACh or changes in postsynaptic membrane 
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resistance or capacitance. If these remain unchanged, then this difference has a pre-synaptic origin, such as 
less ACh contained in each quanta. Additionally, the electrophysiological assessment provides an excellent 
time resolution of events and the method is relatively simple. It constitutes the best way to evaluate the 
nerve-muscle communication and hence to detect impairments (Naguib et al., 2002). 
 
3.4.2 Diaphragm phrenic-nerve preparation 
Experiments were conducted in animals with 4-6 and 12-14 weeks-old. Non-transgenic littermates 
(WT) were used as age-matched controls. At the different stages of disease, mice were anesthetized with 
gaseous isoflurane and then sacrified by decapitation. Hemi-diaphragm muscle with its attached phrenic-
nerve was isolated and then mounted on a 3ml Perspex chamber in order to be maintained at resting 
tension as illustrated in figure 3.4. Tissue was perfused continuously with a gassed (95% O2 and 5% CO2) 
physiological saline solution (containing (mM): NaCl 117; KCl 5; NaHCO3 25; NaH2PO4 1,2; glucose 11; CaCl2 
2,5; MgCl2 1,2) kept at room temperature (22-25ºC). Perfusion was maintained at a rate of 3ml/min via a 
roller pump, and bath volume was kept constant by suction. 
 
 
 
 
 
 
 
 
 
Figure 3.4 Scheme depicting diaphragm phrenic-nerve preparation  
A) Phrenic motor neurons together with a strip of the innervated diaphragm muscle and ribs are isolated 
(adapted from Mantilla and Sieck 2009) and then B) assembled in a perspex chamber to be maintained at 
resting tension. 
 
 
 
Perspex  
chamber 
Phrenic-nerve 
Diaphragm muscle 
Ribs 
A 
B 
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3.4.3 Muscle contraction blockade 
Before any recording, muscle action potential had to be blocked in order to prevent mechanical 
disturbance resulting from muscle contraction. This can be achieved by 1) raising [Mg2+] or lowering [Ca2+],  
2) treating preparations with d-tubocurarine, or 3) damaging muscle fibers. In the framework of this study, 
however, these alternative approaches present the limitation that they do not allow the full effect of nerve 
activity to be measured. By contrast, the use of µ-conotoxin GIIIB, a natural toxin isolated from the venom 
of the snail Conusgeographus, allows EPP recording from intact muscle fibers without affecting quantal 
content of EPPs. This inhibitory peptide preferentially blocks muscle Na+ channels and not those present on 
nerves (Cruz et al., 1985). In this study, muscle contraction was prevented by treating preparations with 
2µM µ-conotoxin GIIIB for 45 to 60min, as done previously (Gillingwater et al., 2002). For this purpose, 
perfusion was stopped and toxin was applied to the solution bath, just beneath tissue preparation. During 
time treatment, preparation was kept under oxygenation. At the end, perfusion was retaken by turning on 
the roller pump. This procedure was repeated whenever contraction became visible. 
 
3.4.4 Intracellular recordings 
 
 
 
 
 
 
 
 
Figure 3.5. Diagram of the electrophysiological setup 
The interface board first converts digital signals into analog allowing the computer to send command 
signals (stimulus duration, frequency, strength) to stimulate the nerve. Then, the current is delivered from 
the stimulator through the stimulus isolator (SI) and a suction electrode is use to stimulate the motor axons 
into firing action potentials. The resting membrane potentials (through channel 1) and spontaneous or 
evoked activity (through channel 2) are recorded simultaneously by the microelectrode and then sent into 
the amplifier through corresponding channels. Once amplified, the electrical (analogue) signals travel to the 
interface board to be converted into digital forms and then acquired by the computer using specially 
designed software. 
 
SI 
Stimulator Amplifier 
Interface 
Computer 
Stimulating 
electrode 
Recording 
electrode 
 
Reference 
electrode 
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Data acquisition 
Intracellular recordings were performed in the conventional way (figure 3.5) (Ribeiro and Walker 1975; 
Ribeiro and Sebastiao 1987; Pousinha et al., 2012). Glass microelectrodes (10-30mΩ) filled with 3KCl were 
inserted within muscle fibers at the motor endplate and the reference electrode was an Ag-AgCl pellet 
placed in the bath.  
For EPP recordings, the phrenic-nerve was stimulated supramaximally at 0.5 Hz, with constant current 
of 20 µs duration, by means of a suction electrode. It is known that quantal release, which is itself 
frequency dependent, gradually declines in response to stimulation frequencies greater than 1 Hz. Hence, 
the frequency of stimulation chosen ensured the measurement of individual responses to evoked activity 
without summation of postsynaptic potentials over time.  
MEPPs were acquired in gap free mode during 100s. Through all the experiment, resting membrane 
potential (RMP) of the muscle fiber was monitored. 
After recording, signals were amplified, digitalized and stored on a computer with Clampex program 
(pClamp10 Axon Instruments, Foster City, USA), to offline analysis of data. 
 
Data offline analysis 
The neuromuscular junctions considered for analysis had to meet 2 conditions: a stable resting 
membrane potential ranging from -50mV to -80mV and recordings in gap free mode with a basal noise 
lower than 0.3mV.  
The evoked activity was measured during intervals of 10 minutes. The EPP amplitude represents the 
amplitude of 60 consecutive sweeps. As the magnitude of the recorded EPP is influenced by capacitive 
properties of the muscle fiber membrane (see Wood and Slater 2001) amplitudes were normalized to a 
membrane potential of -75 mV,  as done previously (Sons and Plomp 2006; Pardo et al., 2006; Rozas et al., 
2011) using the following equation; 
VNOR = [VOBS x (-75)] / RMP 
VNOR indicates the corrected amplitude, VOBS the recorded amplitude and RMP the recorded resting 
membrane potential. This normalization allows the correction of the EPP amplitude from subtle changes in 
the resting membrane potential and/or subsequent comparisons of EPP amplitudes from neuromuscular 
junctions with different membrane potentials. Then, the mean amplitude of EPPs was calculated for each 
neuromuscular junction by averaging the 5 normalized EPP amplitudes. The quantal content of the EPPs, 
which indicates the number of vesicles released per impulse, was estimated through the indirect method as 
follows; 
mean QC = mean EPPNOR / mean MEPPNOR  
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The mean EPPNOR indicates the average evoked response normalized, and mean MEPPNOR, the average 
spontaneous response normalized, both acquired during the same period. 
Spontaneous events acquired during the time interval of 100s were detected by a detection protocol 
after application of a lowpass filter to attenuate high frequency noise. The threshold for MEPPs detection 
was set at levels between 0.2mV and 1mV of amplitude. This maximum amplitude was established in order 
to treat GMEPPs separately. Additionally, a minimum and maximum of events duration of 2 and 8 ms 
respectively were set in order to prevent signal contamination with electric noise. The mean amplitude of 
MEPPs was calculated by averaging the amplitude of each MEPP recorded. The same procedure was done 
to assess the mean rise-time of MEPPs and mean decay-time of MEPPs. Additionally the mean frequency of 
MEPPs was measured by counting the number of events acquired during the 100s. The minimum amplitude 
for GMEPPs detection was set at 1mV. The mean frequency of GMEPPs was calculated by counting the 
number of these events acquired during the 100s. 
 
3.5 Statistical analysis 
 
All data are presented as mean ± standard error mean (SEM) in each group, with n corresponding to 
the number of animals used or the number of neuromuscular junctions sampled, as indicated in each figure 
or table.  
Statistical significance of differences between means was determined through GraphPad software. The 
parametric Student´s t test was used whenever both groups presented a normal distribution and equality 
of variances. Normality was tested through Shapiro-Wilk test (S-W), which is more appropriate for small 
samples (n<30), and homogeneity of variances tested through F test. Alternatively, the non parametric 
Mann-Whitney U-test (M-W) was applied when one of the groups was non-normally distributed, and 
Student´s t test with Welsh correction, when the equality of variances condition was not met (F test 
p<0.05).  
The frequency distribution of MEPPs amplitude plotted the amplitude of all MEPPs recorded at WT 
and SOD1 neuromuscular junctions. Histograms with a bin width of 0.1mV ranged from 0.2mV to 1mV. 
Then a non-linear regression that better fit the distribution of data was added, being used a Gaussian 
distribution and a Sum of two Gaussians distributions. To evaluate if the model chosen best fitted the 
distribution we looked at R2, which is a measure of goodness of fit. This ratio ranges between 0 and 1, and 
when R2=1 all points lie exactly on the fitted curve.  
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4 Results 
 
 
4.1 Behavioral phenotyping 
To evaluate motor function, mice were tested on the rotarod at several speeds and the latency-to-fall 
(LF), the time that mice spent on the rotating rod, was recorded.  The stage of the disease was determined 
by the evaluation of animal’s performance on rotarod at 10rpm (for more details see methods 3.2.2).  The 
results obtained in the behavioral assessment of mice from both phases are summarized in table 4.I. 
 
4.1.1 Pre-symptomatic phase 
As shown in table 4.I, the mean body weight of 4-6 weeks-old SOD1(G93A) mice (18.0±0.95g, n=11) 
was approximately the same as WT mice (18.5±0.72g, n=16) (p>0.05, Student´s t test). Regarding rotarod 
test, the mean latency-to-fall of 4-6 weeks-old SOD1(G93A) mice did not differ from WT mice neither at 
5rpm (262±14.0s, n=11, and 257±11.8, n=16, respectively, p>0.05, Mann Whitney test), at 10rpm 
(236±21.8s, n=11, and 257±11.8s, n=16, respectively, p>0.05, Mann Whitney test) nor at 15rpm (79.6±14.1, 
n=11, and 138±20.7s, n=16, respectively, p>0.05, Mann Whitney test), confirming the absence of symptoms 
in SOD1(G93A) mice at low speeds. The performance on the rotarod at 25rpm was, however, reduced in 
the SOD1(G93A) group (23.8±3.76s, n=11) when compared to the WT group (80.6±19.2s, n=16) (p<0.05, 
Mann Whitney test), suggesting a motor impairment at high speeds. 
 
4.1.2 Symptomatic phase 
As indicated in table 4.I, differences in the mean body weight between 12-14 weeks old SOD1(G93A) 
and WT mice were not detected (23.5 ± 0.93g, n=10, 23.9 ± 0.89g, n=10, in WT and SOD1 groups, p>0.05, 
Student´s t test). The performance of SOD1(G93A) mice on the rotarod task was significantly decreased 
when compared to WT mice. The mean latency-to-fall, not different between groups at 5rpm (267 ± 12.3s, 
n=10, 246 ± 23.6s n=10, in WT and SOD1(G93A) groups, p>0.05, Mann Whitney test), became significantly 
reduced by 31% at 10rpm (263±13.9s, n=10, and 181±31.3s, n=10, in WT and SOD1(G93A) groups, p<0.05, 
Mann Whitney test) 59% at 15rpm (218±20.2s, n=10, and 90.4±15.2s, n=10, in WT and SOD1(G93A)  
groups, p<0.05, Student´s t test) and 76% at 25rpm (125±28.7s, n=10, and 29.7±3.54s, n=10, in WT and 
SOD1(G93A) groups, p<0.05, Student´s t test with Welsh correction) indicating an impaired motor balance 
and coordination. We therefore confirmed the symptomatic state of 12-14 weeks old SOD1(G93A) mice. 
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Table 4.I. Motor profile of the pre-symptomatic and symptomatic SOD1(G93A) mice. 
 4-6 weeks old 12-14 weeks old 
 WT SOD1(G93A) WT SOD1(G93A) 
n (mice) 16 11 10 10 
Body weight (g) 18.5 ± 0.72 18.0 ± 0.95 23.5 ± 0.93 23.9 ± 0.89 
LF at 5rpm (s) 242 ± 13.4 262 ± 14.0 267 ± 12.3 246 ± 23.6 
LF at 10 rpm (s) 257 ± 11.8 236 ± 21.8 263 ± 13.9 181 ± 31.3# 
LF at 15 rpm (s) 138 ± 20.7 79.6 ± 14.1 218 ± 20.2 90.4 ± 15.2* 
LF at 25 rpm (s) 80.6 ± 19.2 23.8 ± 3.76# 125 ± 28.7 29.7 ± 3.54+ 
The values are mean ± SEM. Results obtained from aged-matched SOD1(G93A) and WT mice were 
compared. (*p<0.05 for Student´s test; #p<0.05 for Mann-Whitney U-test; +p<0.05 Student´s test Welsh). 
LF, latency-to-fall; rpm, rotations-per-minute. 
 
4.2 Neuromuscular transmission  
 
4.2.1 Pre-symptomatic phase 
To investigate if neuromuscular transmission is changed in the pre-symptomatic phase of ALS, we first 
assessed the evoked and spontaneous activity in phrenic-nerve diaphragm preparations from mice with 4-6 
weeks-old. 
 
Evoked Activity 
The evoked response of pre-symptomatic SOD1(G93A) mice is presented in figure 4.1.A. As illustrated 
in table 4.II, pre-symptomatic SOD1(G93A) mice presented a mean amplitude of EPPs significantly higher 
than WT mice (15.1±1.59mV, n=25, in WT and 26.6±2.37mV, n=22, in SOD1(G93A) mice, p<0.05, Student´s t 
test). This difference was maintained either after normalization of muscle fiber resting membrane potential 
to -75mV (17.0±1.20mV, n=25, in WT and 29.5±2.14mV, n= 22, in SOD1(G93A) mice, p<0.05, Student´s t 
test). Similarly, the mean quantal content of SOD1(G93A) mice was significantly enhanced by approximately 
50% in relation to WT mice (27.2±1.66, n=25, in WT and 40.7±3.09, n= 22, in SOD1(G93A) mice, p<0.05, 
Student´s t test with Welsh correction). As the mean resting membrane potential did not differ between 
WT and SOD1(G93A) mice (-68.7±2.17, n=25, and -67.0±2.67, n= 22, respectively, p>0.05, Student´s t test), 
these differences are not related to changes in muscle fibers viability (table 4.II). 
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Table 4.II. The evoked transmitter release at the diaphragm neuromuscular junctions of pre-symptomatic 
and symptomatic SOD1(G93A) mice. 
 4-6 weeks old 12-14 weeks old 
 WT  SOD1(G93A) WT  SOD1(G93A)  
n (fiber, mice)  25, 13 22, 9 30, 11 39, 11 
EPPs amplitude (mV) 15.1 ± 1.59 26.6 ± 2.37*  21.0 ± 2.45 18.3 ± 1.88 
EPPs amplitudeNOR (mV) 17.0 ± 1.20 29.5 ± 2.14* 23.6 ± 2.21 20.7 ± 2.00 
Quantal content NOR 27.2 ± 1.66 40.7 ± 3.09 
+ 41.3 ± 3.79 35.8 ± 2.74 
The values are mean ± SEM. Results obtained from age-matched SOD1(G93A) and WT mice were 
compared. (*p<0.05 for Student test; +p<0.05 for Student test Welsh). EPP, endplate potential; EPPNOR, 
amplitude of endplate potential normalized to a resting membrane potential of -75mV, Quantal contentNOR, 
normalized quantal content of EPPs (meanEPPNOR/meanMEPPNOR). 
 
 
Table 4.III. Passive properties and spontaneous transmitter release at the diaphragm neuromuscular 
junctions of pre-symptomatic and symptomatic SOD1(G93A) mice. 
The values are mean ± SEM. Results obtained from age-matched SOD1(G93A) and WT mice were 
compared. (*p<0.05 for Student test; #p<0.05 for Mann-Whitney U-test; +p<0.05 for Student Welsh 
correction). RMP, resting membrane potential; MEPP, miniature endplate potential; NMJ, neuromuscular 
junction; GMEPP, giant miniature endplate potential, Ratio, GMEPPs frequency/MEPPs frequency. 
 
Spontaneous activity 
The enhancement of the neuromuscular transmission can be caused by either pre- or post-synaptic 
factors. To get more insights into the underlying mechanism, we looked at spontaneous events. 
 4-6 weeks old 12-14 weeks old 
 WT SOD1(G93A) WT SOD1(G93A) 
n (fiber, mice)  25, 13 22, 9 30, 11 39, 11 
RMP (mV) -68.7 ± 2.17 -67.0 ± 2.67 -64.8 ± 2.50 -65.8 ± 1.69 
     
MEPPs amplitude (mV) 0.54 ± 0.04 0.63 ± 0.03 # 0.50 ± 0.03 0.49 ± 0.03 
MEPPs rise-time (ms) 1.17 ± 0.07 1.01 ± 0.08 # 0.98 ± 0.07 1.15 ± 0.07 
MEPPs decay-time (ms) 3.80 ± 0.15 3.62 ± 0.18 3.12 ± 0.14 3.21 ± 0.13 
MEPPs frequency (s-1) 0.59 ± 0.09 0.61 ± 0.10 0.76 ± 0.11 0.80 ± 0.11 
     
NMJ with GMEPPs (n)  16 18  16  20  
GMEPPs frequency (s-1) 0.22 ± 0.07 0.58 ± 0.13 # 0.44 ± 0.12 0.32 ± 0.10 
Ratio 1.11 ± 0.51 2.38 ± 0.66 1.58 ± 0.49 1.21 ± 0.68 
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To evaluate a possible post-synaptic influence we looked at the amplitude of MEPPs. As indicated in 
table 4.II and figure 4.1, the mean amplitude of MEPPs was significantly higher in SOD1(G93A) mice by 
approximately 17% when compared to WT mice (0.54±0.04mV, n=25, in WT and 0.63±0.03mV, n=22, in 
SOD1(G93A) mice, p<0.05, Mann Whitney test). This difference is more outstanding when looking at the 
distribution of MEPPs amplitudes (figure 4.1.B) and at the Gaussian functions that shape the scatter of data 
(being the values for R2, 0.92 and 0.94, in WT and SOD1(G93A) curves respectively) (figure 4.1.C). As 
illustrated, the SOD1(G93A) distribution presents a pronounced skewing to the right, highlighting the shift 
to larger amplitudes of MEPPs in this group.  
Variations in the amplitudes of MEPPs can be either a consequence of post-synaptic changes in the 
density or kinetic properties of nicotinic ACh receptors and ACh degradation, or pre-synaptic changes, 
namely in the ACh content of one vesicle (quantum). In this way we next evaluated if the density or kinetic 
properties of nicotinic ACh receptors (mean rise-time) and enzymatic properties of acetylcholinesterase 
(mean decay-time) were altered in SOD1(G93A) mice. As indicated in table 4.III, SOD1(G93A) mice exhibited 
a mean rise-time of MEPPs significantly decreased (1.17±0.07ms, n=25, in WT and 1.01±0.08ms, n= 22, in 
SOD1(G93A) mice, p<0.05, Mann Whitney test) and no differences of the mean decay-time of MEPPs 
(3.80±0.15ms, n=25, in WT and 3.62±0.18ms, n= 22, in SOD1(G93A) mice, p>0.05, Mann Whitney test) 
when compared to WT mice, suggesting that the density and/or conductivity to cations of nicotinic ACh 
receptors is higher at SOD1(G93A) mice motor endplates. 
To further evaluate a possible pre-synaptic influence we then looked at the frequency of spontaneous 
events. As shown in table 4.III and figure 4.1.E, the mean frequency of MEPPs in SOD1(G93A) mice 
(0.61±0.10s-1, n=22) did not differ from WT mice (0.59±0.09s-1, n=25) (p>0.05, Mann Whitney test). The 
frequency of GMEPPs was also evaluated. GMEPPs do not enter into the composition of evoked 
monoquantal EPPs and they are indicative of impairments in the basal levels of Ca2+. As illustrated in figure 
4.1.D,E and table 4.III, the presence of neuromuscular junctions exhibiting GMEPPs were more frequent in 
SOD1(G93A) mice (18 out of 22 neuromuscular junctions, 82%) than in WT mice (16 out of 25 
neuromuscular junctions, 64%). Also, the mean frequency of GMEPPs was also significantly increase in 
SOD1(G93A) mice (0.58±0.13 s-1, n=18) in relation to the WT mice (0.22±0.07 s-1, n=16) (p<0.05, Mann 
Whitney test).  To evaluate the probability of GMEPPs occurrence between groups, the mean Ratio 
(frequency of GMEPPs/frequency of MEPPs) was calculated for the neuromuscular junctions presenting 
giant events. As shown in table 4.III, the mean Ratio in SOD1(G93A) group (2.38±0.66) was increased by two 
folds when compared with WT group (1.11±0.51) (p>0.05, Mann Whitney test), suggesting that the 
intracellular Ca2+ level is higher in SOD1(G93A) mice. 
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Figure 4.1 The neuromuscular transmission of the SOD1(G93A) mice in the pre-symptomatic phase of the 
disease. 
A) Illustrates raw recordings of 5 EPPs from (4-6 weeks old) WT and pre-symptomatic SOD1(G93A) mice. B) 
Shows the frequency histogram of MEPPs amplitudes, which pools the amplitude of all MEPPs recorded at 
WT (1398 MEPPs) and SOD1(G93A) (1342 MEPPs) fibers. C) Presents the nonlinear regression applied to WT 
and SOD1(G93A) distributions. As illustrated, both distributions were best fitted with a Gaussian function. 
In D) are shown examples of a MEPP (<1mV) and a GMEPP (>1mV) and in E) examples of spontaneous 
events recorded in gap free mode across 10s in WT and SOD1(G93A) neuromuscular junctions.  
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4.2.2 Symptomatic phase 
To explore if neuromuscular transmission is altered in the symptomatic phase, we also assessed the 
evoked and spontaneous response of phrenic-nerve diaphragm preparations from mice with 12-14 weeks-
old. 
 
Evoked Activity 
The evoked response of symptomatic SOD1(G93A) mice is presented in figure 4.2. As indicated in table 
4.II, symptomatic SOD1(G93A) mice revealed a slight decrease of both mean amplitude of EPPs 
(21.0±2.45mV, n=30, in WT and 18.3±1.88mV, n=39, in SOD1(G93A) mice, p>0.05, Mann Whitney test) and 
mean quantal content (41.3±3.79, n=30, in WT and 35.8±2.74, n=39, in SOD1(G93A) mice, p>0.05, Mann 
Whitney test) when comparing to WT group (table 4.II). The mean resting membrane potential was 
maintained between groups (-64.8±2.50, n=30, -65.8±1.69, n=39, in WT and SOD1(G93A) mice, p>0.05, 
Student´s t test), indicating no changes in the viability of muscle fibers (table 4.II). 
 
Spontaneous activity 
Although the evoked release of symptomatic SOD1(G93A) mice seemed to be unchanged when 
compared to age-matched WT mice, spontaneous activity was also studied.  
As shown in table 4.III and illustrated in figure 4.2.B, the mean amplitude of MEPPs did not vary 
between WT and SOD1(G93A) mice (0.50±0.03mV, n=30, and 0.49±0.03mV, n= 39, respectively, p>0.05, 
Mann Whitney test) indicating no apparent changes in the post-synaptic cell. We noticed however, that the 
distribution of SOD1(G93A) MEPPs amplitudes did not follow a Gaussian distribution. Instead, a sum of two 
Gaussian functions best fitted the distribution of SOD1(G93A) data, shown in figure 4.2.C (first peak at 
0.31±0.01 mV and second peak at 0.63±0.01mV,R2=0.996), raising the possibility of two populations of 
neuromuscular junctions. To investigate this, we established the mean amplitude of SOD1(G93A) MEPPs 
(0.49mV) as a limit to categorize them into two groups – group A with a mean amplitude of MEPPs lower 
than 0.49mV and group B equal or higher than 0.49 – which will be referred to as SOD1a and SOD1b, 
respectively, in the following text. As illustrated in figure 4.2.D, the new distributions of MEPPs amplitudes 
from both groups of neuromuscular junctions were best fitted with Gaussian functions. As their peak 
amplitudes (Group SOD1a peak amplitude at 0.30±0.01mV, R2=0.90, and Group SOD1b peak amplitude at 
0.65±0.01mV, R2=0.97) matched the two peak amplitudes from the bimodal curve, we could validate the 
grouping.   
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Regarding the frequency of spontaneous events, the mean frequency of MEPPs did not differ between 
WT and symptomatic SOD1(G93A) mice (0.76±0.11s-1, n=30, and 0.80±0.11 s-1, n= 39, respectively, p>0.05, 
Mann Whitney test). Also, SOD1(G93A) mice presented a lower number of neuromuscular junctions with 
GMEPPs, being the proportion reduced from approximately 53% in WT (16 out of 30 neuromuscular 
junctions) to 26% in SOD1(G93A) group (20 out of 39 neuromuscular junctions). The mean frequency of 
GMEPPs was slightly reduced by approximately 27% in SOD1(G93A) mice (0.32±0.10s-1, n=20) in relation to 
WT mice (0.44±0.12s-1, n=16) (p>0.05, Mann Whitney test). Accordingly, the mean ratio was decreased by 
23% in SOD1(G93A) group (1.21±0.68, n= 39) when compared to WT mice (1.58±0.49, n=30) (p>0.05, Mann 
Whitney test). 
 
Symptomatic SOD1(G93A) motor endplates 
After the establishment of symptomatic SOD1(G93A) groups of neuromuscular junctions, the evoked 
and spontaneous parameters were re-analyzed in order to delineate the profile of each group (summarized 
in table 4.I). As indicated in table 4.IV, SOD1a neuromuscular junctions presented a mean amplitude of EPPs 
significantly reduced in relation to WT group (21.0±2.45mV, n=30, in WT and 11.4±2.00mV, n=19, in SOD1a, 
p<0.05, Mann Whitney test). Although the quantal content of EPPs was slightly decreased (41.3±3.79, n=30, 
in WT and 32.7±4.40, n=19, in SOD1a, p>0.05, Mann Whitney test) the statistical significance was not 
reached.  
The mean frequency of MEPPs was approximately the same in both SOD1a and WT groups 
(0.76±0.11s-1, n=30, and 0.61±0.11 s-1, n= 19, respectively, p>0.05, Mann Whitney test). GMEPPs were, 
however, less frequent in SOD1a group (3 out of 19 neuromuscular junctions, 16%) than in WT (16 out of 30 
neuromuscular junctions, 53%). Also, SOD1a neuromuscular junctions exhibited a lower mean frequency of 
GMEPPs when compared with WT group (0.44±0.12s-1, n=16 in WT and 0.07±0.03 s-1, n=3, in SOD1a, 
p<0.05) (Student t test with Welsh correction) as well as a lower mean ratio between the frequency of 
GMEPPs over the frequency of MEPPs (1.58±0.49, n=30, in WT and 0.11±0.07, n=3, in SOD1a)  (p<0.05, 
Student t test with Welsh correction). 
SOD1a presented a lower mean amplitude of MEPPs (0.50±0.03mV, n=30 in WT and 0.32±0.02, n= 19, 
in SOD1a, p<0.05, Mann Whitney test), a higher mean rise-time (0.98±0.07ms, n=30, in WT and 
1.39±0.12ms, n=19, in SOD1a) (p<0.05, Mann Whitney test), and no differences in the mean decay-time of 
MEPPs (3.12±0.14ms, n=30, in WT and 3.12±0.17ms, n=19, in SOD1a, p>0.05, Mann Whitney test), 
suggesting changes in the density and/or in conductivity to cations of nicotinic ACh receptors at these 
SOD1(G93A) motor endplates.    
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Table 4.IV. The neuromuscular transmission of the two populations of neuromuscular junctions (SOD1a 
and SOD1b) detected in symptomatic SOD1(G93A) mice. 
The values are mean ± SEM. Results from SOD1a and SOD1b NMJs were compared with age-matched WT 
NMJs (indicated with WT symbol next to the statistical significance) and with each other (indicated with 
SOD1a symbol next to the statistical significance). (*p<0.05 for Student t test; #p<0.05 for M-W test; 
+p<0.05). RMP, resting membrane potential; EPP, endplate potential, MEPP, miniature endplate potential; 
GMEPP, giant miniature endplate potential; Ratio, (frequency of GMEPP)/ frequency of MEPP). 
 
 
 
 
Figure 4.2 The neuromuscular transmission of the SOD1(G93A) mice in the symptomatic phase of the 
disease. 
A) Illustrates raw recordings of 5 EPPs from symptomatic WT mice and the two groups of symptomatic 
SOD1(G93A) neuromuscular junctions, SOD1a and SOD1b. B) Shows the frequency histogram of MEPPs 
amplitudes, that pools the amplitude of all MEPPs recorded at WT (2288 events) and SOD1(G93A) (3674 
events) fibers. C) Shows the nonlinear regressions that better shape WT (Gaussian function) and 
SOD1(G93A) (sum of two Gaussians) data. As illustrated SOD1(G93A) data follows a bimodal curve with two 
peak amplitudes, pointing to the existence of 2 groups of neuromuscular junctions. D) After categorizing 
the two groups, the distributions of MEPPs amplitudes from SOD1a and SOD1b groups were drawn and 
best-fitted with Gaussian functions. As it is visible, the peak amplitude from both distributions matches the 
two peak amplitudes from the bimodal curve, validating the grouping. E) Shows examples of spontaneous 
events recorded in gap free mode across 10s in WT, SOD1a and SOD1b neuromuscular junctions. 
 12-14 weeks old 
 WT SOD1a SOD1b 
n (fibers) (30) (19) (20) 
RMP (mV) -64.8 ± 2.50 -64.4 ± 2.05 -67.1 ± 2.67 
    
EPPs amplitude (mV) 21.0 ± 2.45 11.4 ± 2.00 #WT 24.9 ± 2.33 #SOD1a 
Quantal contentNOR 41.3 ± 3.79 32.7 ± 4.40 38.8 ± 3.30 
    
MEPPs amplitude (mV) 0.50 ± 0.03 0.32 ± 0.02 #WT 0.64 ± 0.02 #WT ; #SOD1a 
MEPPs rise-time (ms) 0.98 ± 0.07 1.39 ± 0.12 #WT 0.93 ± 0.06 #SOD1a 
MEPPs decay-time (ms) 3.12 ± 0.14 3.12 ± 0.17 3.28 ± 0.20 
MEPPs frequency (s-1) 0.76 ± 0.11 0.61 ± 0.11 1.26 ± 0.33 
    
NMJ with GMEPPs (n) 16 3 17 
GMEPPs frequency (s-1) 0.44 ± 0.12 0.07 ± 0.03 +WT 0.38 ± 0.12 +SOD1a 
Ratio 1.58 ± 0.49 0.11 ± 0.07 +WT 1.40 ± 0.80     
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In contrast, SOD1b neuromuscular junctions did not show significant differences when compared to 
WT group in most of the parameters investigated, being the mean amplitude of MEPPs the exception. As 
indicated in table 4.IV, the mean amplitude of MEPPs in SOD1b was significantly higher than in WT fibers 
(0.50±0.03mV, n=30 in WT fibers and 0.64±0.02, n=20, in SOD1b, p<0.05, Mann Whitney test).  
 
4.2.3 Comparison between phases 
 
To clarify how the neuromuscular transmission evolved from pre-symptomatic to symptomatic 
SOD1(G93A) mice, from now on referred to as preSOD1(G93A) and sympSOD1(G93A) respectively, we 
further compared both phases of the disease. 
 
Pre-symptomatic SOD1(G93A) vs. Symptomatic SOD1(G93A) 
We first compared preSOD1(G93A) with sympSOD1(G93A) mice. This, despite disregarding the 
existence of two neuromuscular junction groups, shows the averaged, and so, the overall neuromuscular 
transmission evolution. As we can see from figures 4.3, symptomatic SOD1(G93A) mice revealed a marked 
reduction of the mean amplitude of EPPs (26.6±2.37mV, n=22, in preSOD1(G93A) and 18.3±1.88mV, n=39, 
in sympSOD1(G93A), p<0.05, Student t test) and no significant variation of the mean quantal content of 
EPPs (p>0.05, Mann Whitney test), when compared to pre-symptomatic SOD1(G93A) group. This negative 
trend contrasts with the positive trend from WT group which shows an increase of both mean amplitude of 
EPPs (p>0.05) and mean quantal content (p<0.05, Student t test), between these periods of time.  
Regarding spontaneous activity, symptomatic SOD1(G93A) mice presented a mean amplitude of 
MEPPs markedly reduced (0.63±0.03mV, n=22, in preSOD1(G93A)  and 0.49±0.03, n=39, in 
sympSOD1(G93A), p<0.05, Mann Whitney test) and no changes in the mean frequency of MEPPs. They 
revealed a slight reduced mean frequency of GMEPPs (p>0.05) and reduced mean ratio (2.38±0.66, n=22, in 
preSOD1(G93A)  and 1.21±0.68, n=39, in sympSOD1(G93A), p<0.05, Mann Whitney test). 
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Figure 4.3 Evolution of the neuromuscular transmission from pre-symptomatic to symptomatic phases of 
the disease 
Here is summarized the comparisons between pre-symptomatic and symptomatic WT mice (white bars) as 
well as pre-symptomatic and symptomatic SOD1(G93A) mice (grey bars) regarding the mean A) amplitude 
of EPPs, B) quantal content, C) amplitude of MEPPs, D) frequency of MEPPs, E) frequency of GMEPPs and F) 
ratio. Regarding the SOD1(G93A) mice, pre-symptomatic results were also compared to the two groups of 
neuromuscular junctions found in symptomatic mice (grey bars in a grey background). The significance of 
these comparisons, between animals from the same genotype but from different ages, are indicated in 
black. The comparisons done in the previous sections, between animals from different genotype but same 
ages, are indicated in grey. (*p<0.05 for Student t test; #p<0.05 for M-W test; +p<0.05).  
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Pre-symptomatic SOD1(G93A) vs. SOD1b 
While looking at the evoked and spontaneous parameters from SOD1b group we noticed a similarity 
with pre-symptomatic SOD1(G93A) group. To test if these could represent the same population of 
neuromuscular junctions, maintained from pre-symptomatic till symptomatic phase, we then compared 
SOD1b to pre-symptomatic SOD1(G93A) group. Interestingly, the SOD1b neuromuscular junctions did not 
differ in any of the studied parameters, showing a similar electrophysiological profile to pre-symptomatic 
SOD1(G93A) (figure 4.3).  
 
Pre-symptomatic SOD1(G93A) vs. SOD1a 
Finally, we compared symptomatic SOD1a with pre-symptomatic SOD1(G93A) neuromuscular 
junctions. As shown in figure 4.3, SOD1a fibers present both mean amplitude of EPPs (26.6±2.37mV, n=22, 
in preSOD1, and 11.4±2.00mV, n=19, in SOD1a, p<0.05, Student t test) and mean quantal content 
(40.7±3.09, n=22, in preSOD1 and 32.7±4.40, n=19, in SOD1a, p<0.05, Student t test) significantly reduced, 
and no differences in the mean resting membrane potential. They also present a marked reduction of the 
mean amplitude of MEPPs (0.63±0.03mV, n=22, in preSOD1, and 0.32±0.02mV, n=19, in SOD1a, p<0.05, 
Mann Whitney test), as well as of the mean frequency of GMEPPs (0.58±0.13s-1, n=22, in preSOD1, and 
0.07±0.03s-1, n=19, in SOD1a, p<0.05, Student t test with Welsh correction) and mean Ratio (2.38±0.66, 
n=22, in preSOD1, and 0.11±0.07, n=19, in SOD1a, p<0.05, Student t test with Welsh correction). 
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5 Discussion 
 
 
The results reported in this work clearly show that the neuromuscular transmission of SOD1(G93A) 
mice presents changes along the progression of the disease. In the pre-symptomatic phase, the synaptic 
transmission at the phrenic-nerve diaphragm neuromuscular junction was enhanced whereas in the 
symptomatic phase two groups of neuromuscular junctions were detected: one group maintained the same 
profile as those from pre-symptomatic phase whereas in the other group, the neuromuscular transmission 
was compromised. 
 
Wild-type mice neuromuscular junctions underwent normal maturation from 4-6 to 12-16 weeks-old 
since they showed an increase in the mean amplitude of EPPs accompanied by an increase of the mean 
quantal content of EPPs. Consistent with this, previous authors have shown that during the first weeks after 
birth there is a dramatic increase in the size of the motor nerve terminal (Slater 1982) which parallels with 
an increase in transmitter release (Diamond and Miledi 1962). Changes in the types of Ca2+ channels 
present at the nerve terminals also occur and were also reported to be involved in the increase of the 
quantal content of EPPs (Rosato Siri and Uchitel 1999). Furthermore, adult wild-type mice showed a 
reduction in both rise-time and decay-time of MEPPs. Accordingly, it is known that the maturation of nerve 
terminal is accompanied by a maturation of the post-synaptic membrane. During this period there is a 
switch in the isoform of acetylcholine receptors from -subunit to -subunit, which leads to receptors with 
higher conductance and shorter mean open times. This period is also characterized by the elaboration of 
the post-synaptic folds, with consequently a redistribution of the voltage-gated Na+ channels (Wood and 
Slater, 2001).  
 
Pre-symptomatic SOD1(G93A) mice presented an enhancement of the mean amplitude of EPPs that 
was accompanied by an increase in the mean quantal content of EPPs, suggesting that more acetylcholine is 
being released to the synaptic cleft. These results point for an early maturation of the neuromuscular 
junctions in SOD1(G93A) mice since pre-symptomatic SOD1(G93A) mice and the adult wild-type mice do 
not present differences in the evoked activity. Therefore, this could be a compensatory response for an 
eventual early denervation. Accordingly, 4-6 weeks-old SOD1(G93A) mice exhibited a significant decrease 
of motor balance and coordination at higher speeds (25rpm) on rotarod suggesting that morphological 
changes like denervation and/or muscle fibers loss has already started. In line with this, previous 
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contractility and morphological studies in SOD1(G93A) mice also reported a decline in the number of motor 
units with a concomitant decline in both twitch and tetanic forces in tibialis anterior (by day 60) and 
gastrocnemius (by day 40) (Hegedus et al., 2008) or withdrawal of neuromuscular junctions in triceps surae 
gluteus and gracilis (by day 50) (Frey et al., 2000). The differences observed in the evoked activity are due 
to both pre- and post-synaptic mechanisms since the mean frequency of GMEPPs (associated with changes 
in the nerve terminal) and mean amplitude of MEPPs (associated with changes in the post-synaptic cell) 
were also enhanced.  
Pre-symptomatic SOD1(G93A) mice showed a higher probability of synchronized spontaneous release 
translated by both the proportion of fibers with spontaneous “giant” events and the mean ratio between 
GMEPPs and MEPPs frequencies. It is known that GMEPPs are generated through a “constitutive secretion” 
of acetylcholine (Sellin et al., 1996), are insensitive to nerve-terminal depolarization and extracellular Ca2+ 
(Colmeus et al., 1982; Thesleff et al., 1983), being triggered by a Ca2+ release from intracellular stores or 
from an impaired processing of recycled vesicles (Rizzoli and Betz 2002). Consistent with this, SOD1(G93A) 
mice have (1) a defective Ca2+ homeostasis (Jaiswal et al., 2009), (2) present dysfunctional mitochondria in 
motor neurons (Kong and Xu, 1998), which have reduced ability to uptake efficiently cytoplasmatic Ca2+ 
(Vila et al., 2003; Damiano et al., 2006; Nguyen et al., 2009) and induces Ca2+ release from endoplasmatic 
reticulum stores in muscle fibers (Zhou et al., 2010). Also, (3) IgG from ALS patients were reported to 
interact with nerve terminals activating IP3 receptors (Pagani et al., 2006). Together, these events may 
cause an increase in the level of cytoplasmatic Ca2+ and, therefore, increase the spontaneous synchronized 
release of acetylcholine.  GMEPPs have been reported to be enhanced under pathological conditions like 
paralysis (paralyzed synapses) (Gundersen 1990), nerve terminal sprouting and synapse remodeling (Miledi 
1960), nerve terminals in degeneration (Birks et al., 1960) and in several motor endplate diseases 
(Weinstein 1980). Thus, the results described in this work suggest that diaphragm muscle from SOD1(G93A) 
mice already presents morphological changes in the pre-symptomatic phase. Consistent with this, Fischer 
and collaborators (2004) performed a spatiotemporal analysis of disease progression in SOD1(G93A) mice 
and they observed that 40% of end-plates were denervated at day 47. Here we show functional evidence 
that molecular and morphological mechanisms related to denervation might start earlier, around day 28.  
SOD1(G93A) mice presented an enhancement of the mean amplitude of MEPPs in the pre-
symptomatic phase that could be related to (1) an increased quantal package of transmitter through larger 
synaptic vesicles, (2) a decreased acetylcholinesterase activity, (3) a higher sensitivity of the muscle fiber to 
acetylcholine associated with higher affinity of nicotinic acetylcholine receptors to their ligand and/or 
higher nicotinic acetylcholine receptors expression or (4) changes in fiber type composition. To our 
knowledge there are no studies addressing acetylcholine content in single vesicles in ALS, although we 
excluded this hypothesis since SOD1(G93A) mice were reported to present ATP impairments (Mattiazzi et 
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al., 2002), disruption of the axonal transport (De Vos et al., 2007) and lower levels of acetylcholine 
transferase at nerve terminals (Tateno et al., 2009) compromising several processes such as ACh synthesis, 
vesicles refilling and/or recycling. We also exclude the decreased acetylcholinesterase activity since the 
mean decay-time of MEPPs recorded in SOD1(G93A) mice was similar to the wild-type mice, indicating that 
the degradation of acetylcholine is not changed in the pre-symptomatic phase of the disease. The 
enhancement in the mean amplitude of MEPPs could be related to changes in the expression/affinity of 
nicotinic acetylcholine receptors at the motor endplate. Narai and collaborators (2009) investigated the 
status of the neuromuscular junction along the disease progression at soleus muscle. They reported that 
the levels of acetylcholine receptors in SOD1(G93A) mice did not change throughout 5-20 weeks of age, 
and acetylcholine receptors remain clustered at neuromuscular junctions. To our knowledge there are no 
studies assessing acetylcholine receptors density/affinity at the diaphragm muscle in this model of ALS. 
However, in this work we observed that SOD1(G93A) mice present a lower rise-time of MEPPs, thereby 
presenting a functional evidence that pre-symptomatic SOD1(G93A) motor endplates might have a higher 
permeability to cations than the wild-type mice. Finally, changes in the mean amplitude of MEPPs could 
also be related to the muscle fiber-type composition, a finding occurring in other motor neuron diseases 
such as severe spinal muscular atrophy (Ruiz et al., 2010). Previous studies have shown that large motor 
neurons, which innervate IIB and IID/X muscle fibers, have higher vulnerability and degenerate prematurely 
(Hegedus et al., 2007; Hegedus et al., 2008). Moreover, pre-symptomatic SOD1(G93A) mice were shown to 
present a significant proportion of atrophic fast-twitch fibers (by day 60) (Atkin et al., 2005). Since the mean 
amplitude of MEPPs is known to be inversely related to muscle fiber diameter (Rowe and Goldspink 1969), 
the proportional increase of muscle fibers type IIA, which present a lower diameter, together with the 
increase atrophy of muscle fibers type IIB and IID/X, could explain the differences observed in the pre-
symptomatic phase of the disease.  
 
Regarding the symptomatic SOD1(G93A) mice we could find two groups of neuromuscular junctions: 
one (group SOD1b) maintained the same enhancement of neuromuscular transmission seen in the pre-
symptomatic phase and the other (group SOD1a) presented a new profile characterized by an impairmed 
neuromuscular transmission (group B). Recently Naumenko and collaborators (2011) reported that the 
amplitude and the quantal content of EPPs, as well as the mean amplitude of MEPPs, recorded in 
symptomatic congenic SOD1(G93A) mice was not different from wild-type mice. Accordingly, if we had 
considered the average of all neuromuscular junctions in which recordings were performed, would achieve 
no differences between symptomatic SOD1(G93A) mice and wild-type mice. However, in the present study 
the distribution of the mean amplitude of MEPPs did not follow a normal Gaussian distribution, suggesting 
the presence of the above neuromuscular junctions groups. Indeed, the existence of different 
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neuromuscular junctions within the same muscle is commonly seen in conditions where there is a scattered 
temporal and spatial pattern of denervation and re-innervation processes across muscle fibers 
(Kretschmannova and Zemkova 2004, Ruiz et al., 2010). Consistent with this, a recent study performed by 
Valdez and collaborators (2012) observed that diaphragm muscle from symptomatic SOD1(G93A) mice 
present approximately 35% of fibers fully innervated, 20% of fibers denervated and 45% of fibers partially 
innervated. Moreover, in the present study some neuromuscular junctions from the symptomatic 
SOD1(G93A) mice presented just synchronous and asynchronous spontaneous activity and lacked an 
evoked response. These events have been reported to occur in other motor neuron diseases (Ruiz et al., 
2010) and after axotomy (Gillingwater et al., 2002).  
Neuromuscular junctions from group SOD1b presented the same profile as pre-symptomatic 
SOD1(G93A)mice, suggesting that, at this point, they were less affected by the disease progression. In 
contrast, neuromuscular junctions from SOD1a presented a significant decrease in the mean amplitude of 
both EPPs and MEPPs, as also a higher mean rise-time of MEPPs when compared to the wild-type mice. 
Altough the mean amplitude was decreased, the quantal content of EPPs was not significantly different, 
suggesting that the nerve terminal maintain its efficiency. In contrast the mean amplitude of MEPPs was 
reduced in the neuromuscular junctions from group SOD1a, suggesting a reduction in the influx of cations 
into the muscle fibers. These changes could be related to (1) a lower sensitivity of the muscle fiber to 
acetylcholine. Although Narai et al. (2009) did not observed changes in the levels and clusters of 
acetylcholine receptors in SOD1(G93A) soleus muscle, recently, Valdez and collaborators (2012), detected 
that neuromuscular junctions from symptomatic SOD1(G93A) EDL muscle presented post-synaptic 
fragmentation and decreased acetylcholine receptors density. This process has also been reported to occur 
during aging (Courtney and Steinbach 1981) and in other neuromuscular junction disorders such as 
Duchenne Muscular Dystrophy (Personius and Sawyer 2006). (2) Changes in the diaphragm muscle fibers 
type morphology. Accordingly, Atkin and collaborators (2005) have shown that gastronecmius muscle from 
SOD1(G93A) mice at the end stage presented hypertrophic slow twitch-fibers. A similar phenomena could 
be occurring at the diaphragm muscle as a compensatory mechanism to the ongoing denervation (3) Also, 
denervation/re-innervation processes which lead to an increase of the distance between the nerve terminal 
and the motor endplate causing a reduction in the neuromuscular junction safety factor cannot be 
excluded. Accordingly, during the process of aging, motor innervations is more instable (Balice-Gordon 
1997). 
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6 Conclusions 
 
 
In conclusion, the work herein reported (summarized in figure 6.1) clearly shows that the 
neuromuscular transmission of SOD1(G93A) mice is enhanced in the pre-symptomatic phase. This probably 
results from an early maturation mechanism or a compensatory response, in order to sustain an effective 
contraction and overcome the early denervation. In the symptomatic phase our results are consistent with 
the hypothesis that the diaphragm of SOD1(G93A) mice are undergoing cycles of denervation/re-
innervation supported by the mixed population of neuromuscular junctions. These early changes in the 
neuromuscular transmission of SOD1(G93A) mice is a novel proof that the ALS associated events start long 
before symptoms onset. Although the evidence suggest that the impairments in the neuromuscular 
transmission seen in SOD1(G93A) mice are due to changes at the motor endplate level, it remains to clarify 
if it supports the dying-back disease hypothesis for ALS. 
 
 
 
Figure 6.1 Hypothesis about the neuromuscular junctions in SOD1(G93A) along disease progression. 
 
WT 
SOD1(G93A) 
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